JP2017508817A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508817A5
JP2017508817A5 JP2017501116A JP2017501116A JP2017508817A5 JP 2017508817 A5 JP2017508817 A5 JP 2017508817A5 JP 2017501116 A JP2017501116 A JP 2017501116A JP 2017501116 A JP2017501116 A JP 2017501116A JP 2017508817 A5 JP2017508817 A5 JP 2017508817A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
intrahepatic cholestasis
compound
methylphenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501116A
Other languages
English (en)
Japanese (ja)
Other versions
JP6568577B2 (ja
JP2017508817A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021502 external-priority patent/WO2015143178A1/en
Publication of JP2017508817A publication Critical patent/JP2017508817A/ja
Publication of JP2017508817A5 publication Critical patent/JP2017508817A5/ja
Application granted granted Critical
Publication of JP6568577B2 publication Critical patent/JP6568577B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501116A 2014-03-20 2015-03-19 肝内胆汁うっ滞症の治療 Active JP6568577B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968037P 2014-03-20 2014-03-20
US61/968,037 2014-03-20
PCT/US2015/021502 WO2015143178A1 (en) 2014-03-20 2015-03-19 Treatment of intrahepatic cholestatic diseases

Publications (3)

Publication Number Publication Date
JP2017508817A JP2017508817A (ja) 2017-03-30
JP2017508817A5 true JP2017508817A5 (https=) 2018-04-19
JP6568577B2 JP6568577B2 (ja) 2019-08-28

Family

ID=52808186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501116A Active JP6568577B2 (ja) 2014-03-20 2015-03-19 肝内胆汁うっ滞症の治療

Country Status (32)

Country Link
US (5) US9486428B2 (https=)
EP (1) EP3119384B1 (https=)
JP (1) JP6568577B2 (https=)
KR (1) KR102000332B1 (https=)
CN (1) CN106102734B (https=)
AU (1) AU2015231232B2 (https=)
BR (1) BR112016020260A8 (https=)
CA (1) CA2941401C (https=)
CL (1) CL2016002338A1 (https=)
CY (1) CY1120927T1 (https=)
DK (1) DK3119384T3 (https=)
EA (1) EA032358B1 (https=)
ES (1) ES2701094T3 (https=)
FI (1) FIC20253004I1 (https=)
FR (1) FR25C1031I2 (https=)
HR (1) HRP20181914T1 (https=)
HU (2) HUE041733T2 (https=)
IL (1) IL247920B (https=)
LT (2) LT3119384T (https=)
MX (1) MX367478B (https=)
NL (1) NL301338I2 (https=)
NO (1) NO2025035I1 (https=)
NZ (1) NZ724057A (https=)
PH (1) PH12016501769B1 (https=)
PL (1) PL3119384T3 (https=)
PT (1) PT3119384T (https=)
RS (1) RS57970B1 (https=)
SI (1) SI3119384T1 (https=)
SM (1) SMT201800690T1 (https=)
UA (1) UA120756C2 (https=)
WO (1) WO2015143178A1 (https=)
ZA (1) ZA201606043B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740874C (en) * 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
DK3973959T3 (da) 2017-09-26 2025-01-20 Cymabay Therapeutics Inc Behandling af kolestatisk kløe med seladelpar
EP3880187A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
JP7731868B2 (ja) 2019-08-02 2025-09-01 エースロット,インコーポレイテッド TDP-43、α-シヌクレイン、ハンチンチンタンパク質及びタウタンパク質のオリゴマー形成に関連する疾患を治療するための小分子薬物、並びに関連する方法
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
WO1996027606A1 (en) 1995-03-06 1996-09-12 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
NZ331217A (en) 1996-02-14 2000-02-28 Novartis Ag Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) * 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
NZ602125A (en) 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
EP3160458A1 (en) 2014-06-26 2017-05-03 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
DK3973959T3 (da) 2017-09-26 2025-01-20 Cymabay Therapeutics Inc Behandling af kolestatisk kløe med seladelpar
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
EP3880185A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash

Similar Documents

Publication Publication Date Title
JP2017508817A5 (https=)
JP2017513836A5 (https=)
JP2017505285A5 (https=)
JP2020535225A5 (https=)
JP2018534348A5 (https=)
HRP20192299T1 (hr) Liječenje nafld i nash
JP2014507446A5 (https=)
JP2012193216A5 (https=)
JP2014515013A5 (https=)
JP2014511891A5 (https=)
JP2014521735A5 (https=)
JP2013525444A5 (https=)
JP2009530398A5 (https=)
JP2016534063A5 (https=)
JP2016510326A5 (https=)
JP2016511753A5 (https=)
JP2015038135A5 (https=)
JP2017520613A5 (https=)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2018537507A5 (https=)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
NZ724057A (en) Treatment of intrahepatic cholestatic diseases
JP2019518022A5 (https=)
JP2014521641A5 (https=)
JP2017505809A5 (https=)